Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (910)	10/22/1997 11:49:00 AM
From: David Bogdanoff	Read Replies (1) \| Respond to of 2173

DR: Good observations on the prognosis for the incomplete studies. However, in your analysis of the putative J&J buyout you ignored the scenario in which Pramlintide sales are just o.k., i.e. enough to make a marketing effort, but not so much as to cause the AMLN management to refuse all reasonable offers. I think this is the most likely prognosis for this product based on current info. and should be considered in any analysis of the company. David